Health Care·Pharmaceuticals·$153.6B
Pfizer Inc. is a leading pharmaceutical company focused on developing and manufacturing innovative medicines and vaccines....
EPS
Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.
Revenue
Total revenue reflects the company's ability to generate sales and is vital for understanding its market performance.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
8Q
EPS Beat Rate
100%
Avg EPS Surprise
+38.48%
Avg Stock Reaction
+1.15%
In the last quarter, Pfizer reported an EPS of $0.66, exceeding expectations by 16.81%. However, the stock price fell by 3.34% the following day, indicating market caution despite the positive earnings surprise.
Management Promises & Guidance
Analysts are cautiously optimistic about Pfizer's upcoming earnings, expecting it to meet or slightly exceed the consensus estimates. The market will closely watch for any updates on product pipelines and sales trends.
Bull Case
If Pfizer beats EPS and revenue estimates, it could signal strong demand for its products, particularly in vaccines, and boost investor confidence.
Bear Case
Conversely, if the company fails to meet expectations, it may raise concerns about declining sales and future growth prospects, leading to a negative market reaction.
EPS
$0.72Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.
Revenue
$13.8BTotal revenue reflects the company's ability to generate sales and is vital for understanding its market performance.
The print will turn on these two things.
Q1
Will EPS exceed the consensus estimate of $0.72?
A significant beat could indicate strong operational performance and boost investor confidence.
Q2
What is the outlook for revenue growth, especially in vaccine sales?
Understanding revenue trends will be crucial for assessing the company's future growth potential.
Why consensus could be wrong
The Street may be underestimating the potential for Pfizer's new product pipeline to drive revenue growth, particularly in emerging markets.
Supporting Evidence
Recent trends in vaccine demand suggest a stronger-than-expected recovery in sales.
Pfizer's historical performance shows a consistent ability to exceed EPS estimates.
Options pricing indicates a lower expected move than historical averages, suggesting a potential mispricing.
Key Risk
If new product sales significantly outperform expectations, it could challenge current consensus estimates.
Pre-commit to what would confirm each case.
The market is debating Pfizer's ability to sustain growth in a competitive pharmaceutical landscape, especially post-pandemic.
Bull Confirmed If
An EPS of $0.80 or higher would confirm the bull case, indicating strong demand and operational efficiency.
Bear Confirmed If
An EPS below $0.56 would confirm the bear case, raising concerns about declining sales and profitability.
Implied Move
±3.3%
Historical Avg
±3.0%
The options market is pricing in a move of approximately 3.3% in either direction following the earnings report, indicating some uncertainty among investors.
Options are pricing ±3.3% while PFE has averaged ±3.0% over the last 8 prints — setup is roughly in line with history.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Pfizer beats expectations, history suggests the stock could rise by around 1.15% on the following day, confirming positive market sentiment.
In-Line / Cautious
If results are in line with expectations, the stock may experience muted movement as investors await further commentary from management.
Miss
A miss on earnings could lead to a decline, with historical patterns suggesting an average drop of around 3.01%.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026